Sugi Predict

Sugi Predict / Compounds / SCHEMBL19851234

SCHEMBL19851234

SCHEMBL19851234

C[C@@H](O)[C@H](N)C(=O)N1CCN(Cc2ccccc2)C2(CNC2=O)C1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CHRM1 P11229 1/20 0.39
▸ OPRD1 P41143 3/20 0.37
▸ OPRK1 P41145 3/20 0.37
▸ MEN1 O00255 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ ALDH1A1 P00352 3/20 0.36
▸ L3MBTL1 Q9Y468 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ DPP4 P27487 3/20 0.35
▸ DPP7 Q9UHL4 2/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ ACE P12821 1/20 0.35
▸ LIPE Q05469 1/20 0.35
▸ OPRM1 P35372 1/20 0.34
▸ OPRL1 P41146 1/20 0.34
▸ KDM4E B2RXH2 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ CYP2D6 P10635 2/20 0.34
▸ SLC6A9 P48067 1/20 0.34
▸ MMP2 P08253 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21051189 1.00 CHRM1 (0.39) CHRM1OPRD1OPRK1MEN1KMT2A
SCHEMBL19839167 1.00 CHRM1 (0.39) CHRM1OPRD1OPRK1MEN1KMT2A
SCHEMBL21051188 1.00 CHRM1 (0.39) CHRM1OPRD1OPRK1MEN1KMT2A
SCHEMBL21104766 0.90 OPRD1 (0.38) CHRM1OPRD1OPRK1MEN1KMT2A
SCHEMBL26426429 0.90 CHRM1 (0.40) CHRM1OPRD1OPRK1MEN1KMT2A
SCHEMBL19839822 0.85 CCR1 (0.38) CHRM1OPRD1OPRK1MEN1KMT2A
SCHEMBL19839826 0.85 CCR1 (0.38) CHRM1OPRD1OPRK1MEN1KMT2A
SCHEMBL26426353 0.84 CHRM1 (0.39) CHRM1OPRD1OPRK1MEN1KMT2A
SCHEMBL21104879 0.80 KMT2A (0.40) MEN1KMT2AACETSHR
SCHEMBL19851188 0.78 OPRD1 (0.43) CHRM1OPRD1OPRK1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3490993-B1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY HONG KONG CO LTD (HK) 2023-12-06 — — EP disclosed
US-20230210851-A1 SPIRO-LACTAM COMPOUNDS AND METHODS OF TREATING VIRAL INFECTIONS USING THE SAME APTINYX INC (US) 2023-07-06 — — US disclosed
US-20230131402-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC (US) 2023-04-27 — — US disclosed
US-20230131402-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC (US) 2023-04-27 — — US disclosed
US-20230131402-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC (US) 2023-04-27 — — US disclosed
US-11376250-B2 Spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2022-07-05 — — US disclosed
US-11376250-B2 Spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2022-07-05 — — US disclosed
CN-109890825-B Spiro-lactam NMDA receptor modulators and uses thereof 阿普廷伊克斯股份有限公司 2022-03-11 — — CN disclosed
US-20210322406-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2021-10-21 — — US disclosed
US-20210322406-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2021-10-21 — — US disclosed
US-10918637-B2 Spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2021-02-16 — — US disclosed
US-10918637-B2 Spiro-lactam NMDA receptor modulators and uses thereof APTINYX INC. (US) 2021-02-16 — — US disclosed
US-20190175588-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2019-06-13 — — US disclosed
US-20190175588-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (HK) 2019-06-13 — — US disclosed
WO-2018026782-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF APTINYX INC. (US) 2018-02-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11376250-B2 Spiro-lactam NMDA receptor modulators and uses thereof GRIN1, GRIN2A, GRIN3A CHRM1 478/4885OPRD1 38/4885OPRK1 30/4885
US-20190175588-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A CHRM1 478/4885OPRD1 38/4885OPRK1 30/4885
US-20210322406-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A CHRM1 478/4885OPRD1 38/4885OPRK1 30/4885
US-10918637-B2 Spiro-lactam NMDA receptor modulators and uses thereof GRIN1, GRIN2A, GRIN3A CHRM1 478/4885OPRD1 38/4885OPRK1 30/4885
US-20230210851-A1 SPIRO-LACTAM COMPOUNDS AND METHODS OF TREATING VIRAL INFECTIONS USING THE SAME ACE, ACE2, PREP CHRM1 4670/4885OPRD1 2074/4885OPRK1 1849/4885
US-20230131402-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF GRIN1, GRIN2A, GRIN3A CHRM1 478/4885OPRD1 38/4885OPRK1 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.